MiR‐17‐92 cluster is overexpressed in a number of tumor types [56], and the miR‐19 family has been shown to be the main oncogenic activator of this cluster through the repression of the tumor suppressor PTEN and the activation of the AKT–mTOR pathway [57]. This evidence concerns the gene MTOR and neoplasm.